Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studies
Author:
Funder
Abbvie Israel
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00277-023-05307-1.pdf
Reference21 articles.
1. Rosiñol L, Oriol A, Teruel AI et al (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8):1589–1596 [Cited 2023 Aug 29]
2. San Miguel JF, Schlag R, Khuageva NK, et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–17 [cited 2022 Jun 19]. Available from: www.nejm.org. Accessed 29 Aug 2023
3. Bahlis NJ, Dimopoulos MA, White DJ, et al (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34(7):1875–84 [cited 2022 Jan 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/32001798/. Accessed 29 Aug 2023
4. Stewart AK, Rajkumar SV, Dimopoulos MA, et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–52 [cited 2022 Jan 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/25482145/. Accessed 29 Aug 2023
5. Moreau P, Masszi T, Grzasko N, et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–34 [cited 2022 Jan 18]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1516282. Accessed 29 Aug 2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3